Table 1 Demographic characteristics and CAM practices used by patients
From: An assessment of the impact of herb-drug combinations used by cancer patients
Characteristic | HDS users (out of 127) (%; 95 % CI) | Non-HDS users (out of 235) (%; 95 % CI) |
|---|---|---|
Age | ||
20–30 | 2 (1.6; 0.4, 5.5) | 0 |
31–40 | 6 (4.7; 2.2, 9.9) | 8 (3.4; 1.7, 6.6) |
41–50 | 14 (11.0; 6.7, 17.7) | 27 (11.5; 8.0, 16.2) |
51–60 | 31 (24.4; 17.8, 32.6) | 44 (18.7; 14.3, 24.2) |
61–70 | 50 (39.4; 31.3, 48.1) | 77 (32.8; 27.1, 39.0) |
> 70 | 24 (18.9; 13.0, 26.6) | 79 (33.6; 27.8, 39.8) |
Gender | ||
Male | 53 (41.7; 33.5, 50.4) | 132 (56.1; 49.8, 62.4) |
Female | 74 (58.3; 49.6, 66.5) | 103 (43.9; 37.6, 50.2) |
Cancer diagnosis | ||
Breast cancer | 40 (31.5; 24.1, 40.0) | 51 (21.7; 16.9, 27.4) |
Prostate cancer | 26 (20.5; 14.4, 28.3) | 35 (14.9; 10.9, 20.0) |
Melanoma | 22 (17.3; 11.7, 24.8) | 55 (23.4; 18.4, 29.2) |
Renal cancer | 4 (3.2; 1.2, 7.8) | 18 (7.6; 4.9, 11.8) |
Brain cancer | 8 (6.3; 3.2, 11.9) | 5 (2.1; 0.9, 4.9) |
Gastro-oesophageal cancer | 3 (2.4; 0.8, 6.7) | 12 (5.1; 2.9, 8.7) |
Pancreatic cancer | 3 (2.4; 0.8, 6.7) | 10 (4.3; 2.3, 7.7) |
Bowel cancer | 6 (4.7; 2.2, 9.9) | 11 (4.7; 2.6, 8.9) |
Othera | 15 (11.8; 6.9, 19.0) | 30 (12.8; 9.1, 17.6) |
Healthcare type | ||
Oncology | 110 (86.6; 79.6, 91.5) | 211 (89.8; 85.3, 93.0) |
Palliative | 17 (13.4; 8.5, 20.4) | 24 (10.2; 6.9, 14.7) |